ASCO 2021 | Tucatinib in HER2+ breast cancer with leptomeningeal metastases

Erica Michelle Stringer-Reasor, MD, University of Alabama at Birmingham, Birmingham, AL, provides an overview of the Phase II trial (NCT03501979) of tucatinib in patients with HER2 positive breast cancer with leptomeningeal metastases. This subset of breast cancer has limited treatment options beyond radiation therapy and currently represents an unmet need in terms of effective treatments. Tucatinib was shown to sufficiently cross the blood-brain barrier, with comparable levels of tucatinib in plasma and cerebrospinal fluid (CSF) found. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.